Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entinostat and Nivolumab With or Without Ipilimumab in Advanced Solid Tumors
NCT02453620Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Feb 2016
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of entinostat in solid tumor and breast cancer, sponsored by National Cancer Institute. Primary endpoint: Incidence of adverse events. Started Feb 2016; status: active, not recruiting.
02
Drugs
entinostat
03
Conditions
solid tumorbreast cancer
Beyond the preview
Go deeper on NCT02453620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02453620.